Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01027182
Recruitment Status : Completed
First Posted : December 7, 2009
Last Update Posted : March 19, 2010
National University Hospital, Singapore
Merck Sharp & Dohme Corp.
Information provided by:
Changi General Hospital

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2010
  Actual Study Completion Date : March 2010

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 23, 2018
Wenning, L. A., E. Hwang, et al. (2008). Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV- Infected Patients Following 48 Weeks of Treatment. ICAAC. Washington DC, USA
Merck &Co Inc. (2007). Isentress (raltegravir) tablets. FDA approved label.